'Controlled studies' presentation slideshows

677 views • 58 slides

913 views • 58 slides

FDA Review of Clinical Data Agalsidase alfa for treatment of Fabry Disease

FDA Review of Clinical Data Agalsidase alfa for treatment of Fabry Disease Transkaryotic Therapies, Inc. FDA/Center for Biologics Evaluation and Research. Agalsidase alfa Introduction.

758 views • 49 slides

FDA Processes for Assuring Safety and Efficacy for Ophthalmic Drugs

FDA Processes for Assuring Safety and Efficacy for Ophthalmic Drugs. Wiley A. Chambers, M.D. Ophthalmology Office of New Drugs Center for Drug Evaluation and Research Food and Drug Administration. Disclaimer.

467 views • 41 slides

FDA Review of Clinical Safety Data Omalizumab for treatment of Allergic Asthma Genentech, Inc.

FDA Review of Clinical Safety Data Omalizumab for treatment of Allergic Asthma Genentech, Inc. FDA/Center for Biologics Evaluation and Research. Omalizumab Overview of Studies. Overview of subjects/studies SAE AE Laboratory findings Antibody formation Summary.

636 views • 36 slides

November 3, 2004

321 views • 11 slides

Chapter 24

Chapter 24. Pregnancy and Breast-Feeding. Pregnancy and Breast-Feeding. Teratogenesis From the Greek (producing a monster) Difficult to identify drugs that are teratogenic Teratogenic effects may not be evident for many years after birth Timing and exposure varies from drug to drug. 2.

270 views • 10 slides

Emil D. Kakkis, M.D., Ph.D. President and Founder EveryLife Foundation for Rare Diseases

Welcome to Workshop #5: Accelerated Approval (AA) in Rare Diseases: Review of a White Paper Proposal. Emil D. Kakkis, M.D., Ph.D. President and Founder EveryLife Foundation for Rare Diseases May 15, 2013 Sofitel Hotel Washington, D.C. Lafayette Square.

203 views • 9 slides

Unanswered Questions about Online Learning in Higher Education

Unanswered Questions about Online Learning in Higher Education. Shanna Smith Jaggars Community College Research Center Teachers College/Columbia University Education Writers Association New Orleans, LA, April 8, 2011. DoE report.

227 views • 8 slides